Source comparison
PT-141 Beginners Guide: Comparison of Melanocortin Agonists
Clinical and research applications increasingly compare bremelanotide against other melanocortin receptor-targeting compounds. This table outlines mechanism distinctions, receptor selectivity profiles, and practical protocol differences. PT-141 (Bremelanotide)
This comparison does not assign a generated winner or score.
- Clinical and research applications increasingly compare bremelanotide against other melanocortin receptor-targeting compounds. This table outlines mechanism distinctions, receptor selectivity profiles, and practical protocol differences.
- PT-141 (Bremelanotide)
- MC3R/MC4R (hypothalamic)
- 2.7 hours
- Subcutaneous
- 1.5–2.5 hours
- FDA-approved melanocortin agonist with clinical trial validation; acts centrally on desire pathways rather than vascular mechanisms; requires reconstitution and refrigerated storage
- Melanotan II
- MC1R/MC3R/MC4R/MC5R (non-selective)
- 33 minutes
- 2–4 hours
- Non-selective melanocortin receptor agonist with broader receptor affinity including MC1R (melanogenesis); not FDA-approved; associated with higher nausea rates and potential cardiovascular effects
- Alpha-MSH (endogenous)
- MC1R/MC3R/MC4R/MC5R
- <10 minutes
- Endogenous release
- Variable
- Natural melanocortin peptide produced by POMC cleavage; rapid enzymatic degradation limits therapeutic utility; PT-141 is a synthetic analog designed for metabolic stability
- Setmelanotide
- MC4R (selective)
- 3.2 hours
- Not applicable
- Highly selective MC4R agonist FDA-approved for rare genetic obesity disorders (POMC/LEPR deficiency); different indication profile from PT-141; chronic daily dosing protocol
- PT-141 represents the only melanocortin agonist with specific FDA approval for applications outside metabolic disorders. The receptor selectivity profile (MC3R/MC4R preference) combined with the cyclic peptide structure that resists enzymatic degradation makes it functionally distinct from non-selective agonists like Melanotan II, despite structural similarity.